As­traZeneca stops PhI­Ia tri­al of in­haled asth­ma drug with Pieris, cra­ter­ing the Boston biotech's shares

Af­ter culling a HER2 drug last sum­mer to fo­cus on an in­haled asth­ma med with As­traZeneca, Pieris Phar­ma­ceu­ti­cals ap­pears to be on thin ice with that pro­gram as well, as the Big Phar­ma end­ed a Phase IIa tri­al.

As­traZeneca in­formed Boston-based Pieris yes­ter­day that it will scrap a Phase IIa study of elarek­ibep af­ter tak­ing a look at safe­ty find­ings from a non-clin­i­cal tox­i­col­o­gy study. The dry pow­der in­haled for­mu­la­tion is al­so known as PRS-060/AZD1402 and is an IL-4 re­cep­tor al­pha in­hibitor.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER